BDB-001 Phase III Trial in ANCA-Associated Vasculitis
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-29
Target enrollment:
Participant gender:
Summary
The primary aim is to study the efficacy of treatment with BDB-001 Injection to induce remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab